Literature DB >> 20013929

Diagnosis and treatment of spontaneous group A streptococcal peritonitis.

O Monneuse1, E Tissot, L Gruner, F Michaillard Kaempf, B Allaouchiche, J Etienne, X Barth.   

Abstract

BACKGROUND: Primary group A streptococcal peritonitis (PSAP) is a rare, fulminant and often fatal infection. The clinical manifestations include diffuse peritoneal signs with toxic shock syndrome and sometimes fasciitis.
METHODS: Patients with PSAP diagnosed between December 2002 and December 2006 were studied retrospectively, focusing on the initial presentation, diagnosis, treatment and outcome.
RESULTS: Six patients were identified (five women and one man). The clinical presentation was heterogeneous. All six patients had diffuse peritonitis, four had toxic shock syndrome on hospital admission and two patients also had fasciitis. All patients were treated surgically, and the final diagnosis was confirmed after operation. There were no deaths, but two patients had aesthetic sequelae owing to necrotizing fasciitis.
CONCLUSION: PSAP is a rare condition, often requiring aggressive surgical treatment. Group A streptococcal peritonitis should be suspected in patients with no radiological evidence of a peritoneal portal of entry and no history of ascites. Copyright 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20013929     DOI: 10.1002/bjs.6822

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  10 in total

1.  Primary peritonitis due to group A Streptococcus in a previously healthy pediatric patient.

Authors:  R Holden; A Wilmer; T Kollman
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

2.  Case 1: A 16-year-old female with left lower-quadrant abdominal pain.

Authors:  Andreanne Benidir; Rodrick Lim
Journal:  Paediatr Child Health       Date:  2014-01       Impact factor: 2.253

3.  Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines ? a commentary and an alternative European approach according to clinical definitions.

Authors:  Christian Eckmann; M Dryden; P Montravers; R Kozlov; G Sganga
Journal:  Eur J Med Res       Date:  2011-03-28       Impact factor: 2.175

4.  Group A Streptococci: A rare and often misdiagnosed cause of spontaneous bacterial peritonitis in adults.

Authors:  Mark Malota; Thomas W Felbinger; Reinhard Ruppert; Natascha C Nüssler
Journal:  Int J Surg Case Rep       Date:  2014-12-11

5.  Group A Streptococcal Peritonitis and Toxic Shock Syndrome in a Postmenopausal Woman.

Authors:  Yuri Iwata; Shigeru Iwase
Journal:  Intern Med       Date:  2017-08-21       Impact factor: 1.271

6.  Successful Treatment of Streptococcal Toxic Shock Syndrome with Both Diffuse Peritonitis and Necrotizing Fasciitis.

Authors:  Shuichi Sato; Masahiro Ito; Tsuyoshi Sakai; Anri Kaneta; Fumie Sato
Journal:  Case Rep Surg       Date:  2018-10-28

7.  Necrotizing fasciitis following primary peritonitis caused by Streptococcus pyogenes with covS mutation in a healthy woman: a case report.

Authors:  Masashi Inoue; Eisuke Kako; Rie Kinugasa; Fumiaki Sano; Hironobu Iguchi; Kazuya Sobue
Journal:  JA Clin Rep       Date:  2019-04-27

8.  Oral Sex following Abortion: Case Report of a Sexually Transmitted Infection of Group A Streptococcus Causing Peritonitis.

Authors:  Kenneth L Chan; Louis-Patrick Haraoui; Walter Demczuk; Marc-Christian Domingo; Eric Bergeron
Journal:  Case Rep Surg       Date:  2022-03-31

9.  Streptococcal toxic shock syndrome with primary group A streptococcus peritonitis in a healthy female.

Authors:  Ahsan Wahab; Bilal Nasir
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-10-15

10.  Treatment with antibodies against primary group A streptococcal peritonitis: A case report and a review of the literature.

Authors:  Daisuke Iitaka; Fumiaki Ochi; Susumu Nakashima; Jyunshin Fujiyama; Mamoru Masuyama
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.